- Home
- NGNE vs NEWT Comparison
NGNE vs NEWT Comparison
Compare NGNE & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- NEWT
- Stock Information
- Founded
- NGNE 2003
- NEWT 1998
- Country
- NGNE United States
- NEWT United States
- Employees
- NGNE N/A
- NEWT N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- NEWT Major Banks
- Sector
- NGNE Health Care
- NEWT Finance
- Exchange
- NGNE Nasdaq
- NEWT Nasdaq
- Market Cap
- NGNE 325.3M
- NEWT 294.8M
- IPO Year
- NGNE N/A
- NEWT N/A
- Fundamental
- Price
- NGNE $18.48
- NEWT $12.37
- Analyst Decision
- NGNE Strong Buy
- NEWT Hold
- Analyst Count
- NGNE 7
- NEWT 4
- Target Price
- NGNE $41.86
- NEWT $13.00
- AVG Volume (30 Days)
- NGNE 110.1K
- NEWT 188.9K
- Earning Date
- NGNE 08-11-2025
- NEWT 07-28-2025
- Dividend Yield
- NGNE N/A
- NEWT 6.14%
- EPS Growth
- NGNE N/A
- NEWT 21.23
- EPS
- NGNE N/A
- NEWT 2.01
- Revenue
- NGNE N/A
- NEWT $364,004,000.00
- Revenue This Year
- NGNE N/A
- NEWT N/A
- Revenue Next Year
- NGNE N/A
- NEWT $12.73
- P/E Ratio
- NGNE N/A
- NEWT $6.15
- Revenue Growth
- NGNE N/A
- NEWT 20.91
- 52 Week Low
- NGNE $6.88
- NEWT $9.12
- 52 Week High
- NGNE $74.49
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- NEWT 61.20
- Support Level
- NGNE $19.59
- NEWT $12.16
- Resistance Level
- NGNE $20.46
- NEWT $12.48
- Average True Range (ATR)
- NGNE 1.23
- NEWT 0.27
- MACD
- NGNE -0.20
- NEWT 0.02
- Stochastic Oscillator
- NGNE 13.37
- NEWT 73.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.